| DB ID | MyCo_2591 |
| Title | Combination of Mycological Criteria: a Better Surrogate to Identify COVID-19-Associated Pulmonary Aspergillosis Patients and Evaluate Prognosis? |
| Year | 2022 |
| PMID | 34985983 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | COVID-19 patients |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | Université de Paris, CNRS, Unité de Mycologie Moléculaire, UMR-2000, Paris, France institutional ethics committee approved the study (IDRCB, 2020-A00256-33; CPP, 11-20-20.02.04.68737). Written information was given to the patient or the next of kin. |
| Site of Infection | Lungs |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | A retrospective observational cohort study was conducted. All successive COVID-19 patients admitted to the four intensive care units (ICUs) of our two university hospitals between 15 March 2020 and 1 March 2021 with a positive severe acute respiratory syndrome coronavi- rus 2 (SARS-CoV-2) PCR test (Cobas SARS-CoV-2 test, Roche, Meylan, France) and $1 respiratory sample (bronchoalveolar lavage [BAL], tracheal aspirate, or sputum) sent to the mycology department were included. Of note, the 105 rst patients included were partially analyzed to assess risk factors associated with CAPA (12). Culture and Aspergillus quantitative PCR (qPCR) were systematically performed on all types of respiratory samples (BAL, sputum, tracheal, or bronchial aspirates). |
| Cohort No. | 176 |
| Age Group | 58-72 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Reports on coronavirus disease 2019 (COVID-19)-associated aspergillosis (CAPA) are increasing but incidence, diagnosis, and management remains unclear. Because no host factor meeting European Organization for Research and Treatment of Cancer and Mycosis Study Group Education and Research Consortium (EORTC/MSGERC) de nitions is present in most patients, alternative classi cations were needed. Despite several attempts to clarify CAPA de nition by expert panels, diagnosis remains arguable. The lack of impact of both antifungal treatment and prophylaxis in many large cohort studies and the impact of prophylaxis on the incidence of CAPA cases lead to the hypothesis that many of these cases may only be colonization rather than infection. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad, Hercules, CA, USA) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA, GM lateral flow assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
